Ebrahim Variava to Viral Load
This is a "connection" page, showing publications Ebrahim Variava has written about Viral Load.
Connection Strength
0,380
-
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):577-579.
Score: 0,108
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
Score: 0,043
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022 09; 9(9):e638-e648.
Score: 0,038
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
Score: 0,037
-
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infect Dis. 2021 Jan 04; 21(1):5.
Score: 0,034
-
Secure Delivery of HIV-Related and Tuberculosis Laboratory Results to Patient Cell Phones: A Pilot Comparative Study. AIDS Behav. 2020 Dec; 24(12):3511-3521.
Score: 0,034
-
Intensified household contact tracing, prevention and treatment support versus enhanced standard of care for contacts of tuberculosis cases in South Africa: study protocol for a household cluster-randomised trial. BMC Infect Dis. 2019 Oct 12; 19(1):839.
Score: 0,031
-
Influenza Viral Shedding in a Prospective Cohort of HIV-Infected and Uninfected Children and Adults in 2 Provinces of South Africa, 2012-2014. J Infect Dis. 2018 09 08; 218(8):1228-1237.
Score: 0,029
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
Score: 0,025